77 recruiting, 31 active not recruiting, 22 completed, 15 not yet recruiting. 84 Phase 2, 42 Phase 1, 25 Phase 3, 3 Phase 4, 1 Early Phase 1.
Follow this drug Literature Review of trastuzumab deruxtecan trials Research Report on trastuzumab deruxtecan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test - Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 31 | 2027-06-01 | 2026-10-19 |
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases Trastuzumab Deruxtecan, Stereotactic Radiosurgery - Breast Cancer, HER2-positive Breast Cancer | Phase 1 | Not yet recruiting | Baptist Health South Florida | 20 | 2027-01-01 | 2026-10-01 |
| Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers Trastuzumab Deruxtecan - HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2 | Phase 2 | Not yet recruiting | University of Chicago | 43 | 2026-11-01 | 2026-01-08 |
| Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer Trastuzumab deruxtecan, Lovastatin - Breast Cancer, Advanced Breast Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 60 | 2026-10-31 | 2026-09-22 |
| A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd Trastuzumab Deruxtecan (T-DXd), Pyrotinib - Breast Cancer | Phase 2 | Not yet recruiting | Fujian Medical University | 28 | 2026-10-10 | 2026-09-23 |
| Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer Biopsy Procedure, Biospecimen Collection, Echocardiography Test - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 36 | 2026-10-06 | 2026-10-16 |
| Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells, Trastuzumab deruxtecan (T-DXd), Rimiducid - Breast Cancer | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2026-10-01 | 2026-08-19 |
| T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd Trastuzumab deruxtecan, Trastuzumab, Pertuzumab - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 200 | 2026-09-18 | 2026-10-16 |
| A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer Patritumab deruxtecan, Trastuzumab deruxtecan - Hormone Receptor Positive, HER2-low or HER2-ultralow | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 220 | 2026-09-17 | 2026-10-01 |
| Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer Trastuzumab emtansine (T-DM1), Trastuzumab deruxtecan (T-DXd), Datopotamab deruxtecan (Dato-DXd) - Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC) | Phase 2 | Not yet recruiting | Fudan University | 225 | 2026-09-10 | 2026-09-17 |
| A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer Trastuzumab Deruxtecan (T-DXd, ENHERTU®) - Breast Cancer | Not applicable | Not yet recruiting | Shuangyue Liu | 30 | 2026-09-07 | 2026-08-24 |
| Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer Sacituzumab Govitecan / Trastuzumab Deruxtecan - Triple Negative Breast Neoplasms, Neoplasm Metastasis | Phase 2 | Not yet recruiting | UNICANCER | 260 | 2026-09-01 | 2026-08-03 |
| A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer BL-M07D1, DS-8201 - Breast Cancer | Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 120 | 2026-08-31 | 2026-09-14 |
| Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 37 | 2026-06-17 | 2026-09-04 |
| Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer Megestrol Acetate + Trastuzumab Deruxtecan, Placebo + Trastuzumab Deruxtecan - Advanced/Metastatic Breast Cancer, HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer | Phase 3 | Recruiting | Sun Yat-sen University | 132 | 2026-06-08 | 2026-08-14 |
| Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer Trastuzumab Rezetecan for Injection (SHR-A1811), Trastuzumab Deruxtecan for Injection (T-DXd) - Advanced Breast Cancer | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 100 | 2026-06-01 | 2026-06-05 |
| A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer Trastuzumab Rezetecan for Injection, Trastuzumab Deruxtecan for Injection - Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer | Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 150 | 2026-04-28 | 2026-05-11 |
| ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer SOC (Standard of care), Bevacizumab, Cetuximab - Dynamic Tumor Resistance, Metastatic Colorectal Cancer | Early Phase 1 | Recruiting | M.D. Anderson Cancer Center | 100 | 2026-04-22 | 2026-10-14 |
| Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study Trastuzumab Deruxtecan and ivonescimab - Breast Cancer | Phase 2 | Recruiting | Fudan University | 53 | 2026-04-01 | 2026-06-15 |
Showing 20 of 157. Sign in to see all of them.
Breast Neoplasms (79) · Neoplasm Metastasis (28) · Stomach Neoplasms (12) · Carcinoma, Non-Small-Cell Lung (11) · Colorectal Neoplasms (10) · Brain Neoplasms (8) · Neoplasms (8) · Adenocarcinoma (6) · Pancreatic Neoplasms (6) · Endometrial Neoplasms (5) · Ovarian Neoplasms (5) · Triple Negative Breast Neoplasms (5) · Esophageal Neoplasms (4) · Recurrence (3) · Salivary Gland Neoplasms (3)
AstraZeneca (26) · Daiichi Sankyo (26) · Fudan University (10) · National Cancer Institute (NCI) (10) · Daiichi Sankyo Co., Ltd. (5) · MedSIR (4) · M.D. Anderson Cancer Center (3) · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (2) · Dana-Farber Cancer Institute (2) · Gruppo Oncologico del Nord-Ovest (2) · Jeeyun Lee (2) · Memorial Sloan Kettering Cancer Center (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · Sun Yat-sen University (2) · UNICANCER (2)
United States (85) · China (53) · Spain (52) · Italy (44) · South Korea (42) · France (41) · Japan (40) · Germany (33) · United Kingdom (33) · Taiwan (31) · Belgium (30) · Canada (28) · Brazil (24) · Australia (22) · Poland (21)
Filippo Pietrantonio, MD (2) · Funda Meric-Bernstam (2) · Jeeyun Lee, Ph, MD (2) · Adriana Kahn, M.D. (1) · Aixa Soyano, MD (1) · Alan L Ho (1) · Alexios Matikas, MD/PhD (1) · Ana Garrido-Castro, MD (1) · Andreas N Saltos (1) · Andrew A Davis, MD (1) · Andrew Davis (1) · Antonio Llombart-Cussac, MD (1)
PMID 37597578, PMID 31825192, PMID 33999422, PMID 35964548, PMID 37086745, PMID 37207306, PMID 38231777, PMID 38442809, PMID 40341124, PMID 42208007, PMID 29037983, PMID 29411933, PMID 31047803, PMID 31047804, PMID 32058843, PMID 32213540, PMID 32469182, PMID 33882206, PMID 33961795, PMID 34263665, PMID 34534430, PMID 35320644, PMID 35324390, PMID 35642907, PMID 35665782, PMID 35941372, PMID 36164935, PMID 36342619, PMID 36379002, PMID 36495879, PMID 36780610, PMID 37179020, PMID 37286557, PMID 37329891, PMID 37488289, PMID 37499870, PMID 37694347, PMID 37870536, PMID 37967136, PMID 38059424, PMID 38233810, PMID 38351187, PMID 38547891, PMID 38592002, PMID 38697155, PMID 38710187, PMID 38825627, PMID 38884900, PMID 38979893, PMID 39012221
2023 (19), 2018 (7), 2019 (5), 2017 (4), 2025 (3), UM1CA186688 (3), UM1CA186689 (2), UM1CA186709 (2), 2016 (1), P30CA033572 (1), U10CA180868 (1), U10CA180888 (1), UM1CA186644 (1), UM1CA228823 (1)